The global branded generics market is projected to reach US$ 414.99 billion by 2028 from US$ 235.86 billion in 2022.
Rising penetration of branded generics and increasing government initiatives for promoting branded generics drive the growth of branded generics market. Encouraging utility of branded generics by healthcare providers and professionals acts as a future trend in the branded generics market.
The Association for Accessible Medicines report states that nearly 3.9 billion generic prescriptions were dispensed in 2016. Therefore, branded generics present a viable opportunity for potential growth for big pharma players. According to the published report by HSRII, the US is the largest pharmaceutical market in the world (US$ 325 billion), accounting for one-third of the global pharmaceutical market, with generics accounting for 84% in terms of sales volume and 28% in terms of sales value. Furthermore, branded generics utilization has increased among the population due to savings provided by the healthcare system and the ability to invest in tomorrow's new medicines. For instance, nearly 3.9 billion prescriptions dispensed in the US are for generics. Moreover, on average, in 2016, the use of generic medicines saved each state US$ 4.9 billion compared to the price of relevant branded medicines. This further means that Medicaid savings averaged US$ 744 million, and state Medicaid savings averaged US$ 1.5 billion per state. Such factors accelerate the demand for branded generics, fueling the overall market growth during the forecast period.
Additionally, the rise in government initiatives for promoting branded generics further is accelerating the adoption of branded generics, ultimately stimulating the overall market growth. A Scientific Electronic Library Online (SciELO) report states that promoting branded generics constitutes a core instrument for countries' national pharmaceutical policies, ultimately reducing drug expenditure with expanding healthcare access. For example, to make quality generic medicines available at affordable prices, Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) was launched by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India in November 2008. The scheme focused on dedicated outlets known as Janaushadhi Kendras, offering generic medicines at affordable prices. Till 2021, 8,012 Janaushadhi Kendras were functional across the country. Moreover, a Food and Drug Administration (FDA) report states that as the FDA approves more branded generics, it results in a drop in cost. Generally, multiple generic drugs for the same product create marketplace competition. For example, a single generic competitor results in price reductions of up to 30%, while five competing generics are associated with a price drop of nearly 85%.
The global branded generics market is segmented based on therapeutic application, distribution channel, drug class, and formulation type. Based on therapeutic application, the branded generics market is segregated into oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, analgesics and anti-inflammatory, and others. The others segment is estimated to account for the largest market share during 2022-2028. However, the oncology segment is likely to register the highest CAGR during the forecast period. Generic drugs are also widely used in supportive care during the chemotherapy treatment for oncology. According to the Indian Council for Medical Research (ICMR), in India, the number of Indians who have cancer is projected to increase from 26.7 billion in 2022. to 29.8 billion by 2025. As per the Pharma Intelligence Center, there are currently 1,351 generic drugs available in India for the treatment of various cancers as of February 26, 2021. Most drugs are for the treatment of hematological malignancies, such as blood cancer (606) and leukemia (428). As the cost of branded drugs is higher than generic drugs, maximum people cannot afford these branded drugs and consume generic drugs. Treatment of cancer is limited by the affordability of patients in many developing countries, including India. Therefore, generic drug manufacturers are manufacturing drugs available at affordable costs, often at less than 10% of the original brand cost. It is observed that there is a three-fold higher prescription of generic brands compared to innovators, accompanied by cost savings of up to 80% per prescription. However, the regulatory environment prevailing in India is favorable to ensure satisfactory generic products. These factors are responsible for the growth of this segment, which, eventually, is expected to aid the growth of branded generics market during the forecast period. The others segment is categorized into infectious diseases, musculoskeletal diseases, respiratory diseases, and oral health.
According to the Centers for Disease Control and Prevention, in 2018, ~100,000 people in the US suffered from various infectious diseases. Thus, the prevalence of infectious diseases and respiratory diseases, which are treated using generics, is mainly driving the others segment, contributing a considerable share in the branded generics market during the forecast period.
The opportunity for global branded generics market is product differentiation. The pharmaceutical industry is one of the most intensively regulated sectors, and as a result of these challenges, returns on R&D investment in the pharmaceutical industry have decreased. One feasible alternative for addressing such challenges is adopting strategies such as product differentiation to reduce development costs and maximize profits. Product differentiation deals with developing innovative products based on an existing product by creating better features, performance, or efficacy. Product differentiation paves the way for strengthening product pipeline and lifecycle management. As generic drugs contain the same active pharmaceutical ingredients as the brand-name product, differentiation in the color, shape, taste, inactive ingredients, preservatives, and packaging result in high demand for branded generics globally. Therefore, differentiation in the final product is expected to offer lucrative growth opportunities for the competitive players in the branded generics market.
Additionally, prominent players in the market are focusing on offering low-cost branded generics to remain competitive in the market. This can be achieved by strategically sourcing raw materials from emerging economies and partnering with suppliers. The above factors support the overall branded generics market growth during the forecast period.
The Pan-Canadian Pharmaceutical Alliance, Canadian Generic Pharmaceutical Association, Centers for Disease Control and Prevention, US Food and Drug Administration, International Finance Corporation, and Indian Brand Equity Foundation are among the primary and secondary sources referred to while preparing the report on the global branded generics market.
Rising penetration of branded generics and increasing government initiatives for promoting branded generics drive the growth of branded generics market. Encouraging utility of branded generics by healthcare providers and professionals acts as a future trend in the branded generics market.
The Association for Accessible Medicines report states that nearly 3.9 billion generic prescriptions were dispensed in 2016. Therefore, branded generics present a viable opportunity for potential growth for big pharma players. According to the published report by HSRII, the US is the largest pharmaceutical market in the world (US$ 325 billion), accounting for one-third of the global pharmaceutical market, with generics accounting for 84% in terms of sales volume and 28% in terms of sales value. Furthermore, branded generics utilization has increased among the population due to savings provided by the healthcare system and the ability to invest in tomorrow's new medicines. For instance, nearly 3.9 billion prescriptions dispensed in the US are for generics. Moreover, on average, in 2016, the use of generic medicines saved each state US$ 4.9 billion compared to the price of relevant branded medicines. This further means that Medicaid savings averaged US$ 744 million, and state Medicaid savings averaged US$ 1.5 billion per state. Such factors accelerate the demand for branded generics, fueling the overall market growth during the forecast period.
Additionally, the rise in government initiatives for promoting branded generics further is accelerating the adoption of branded generics, ultimately stimulating the overall market growth. A Scientific Electronic Library Online (SciELO) report states that promoting branded generics constitutes a core instrument for countries' national pharmaceutical policies, ultimately reducing drug expenditure with expanding healthcare access. For example, to make quality generic medicines available at affordable prices, Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) was launched by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India in November 2008. The scheme focused on dedicated outlets known as Janaushadhi Kendras, offering generic medicines at affordable prices. Till 2021, 8,012 Janaushadhi Kendras were functional across the country. Moreover, a Food and Drug Administration (FDA) report states that as the FDA approves more branded generics, it results in a drop in cost. Generally, multiple generic drugs for the same product create marketplace competition. For example, a single generic competitor results in price reductions of up to 30%, while five competing generics are associated with a price drop of nearly 85%.
The global branded generics market is segmented based on therapeutic application, distribution channel, drug class, and formulation type. Based on therapeutic application, the branded generics market is segregated into oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, analgesics and anti-inflammatory, and others. The others segment is estimated to account for the largest market share during 2022-2028. However, the oncology segment is likely to register the highest CAGR during the forecast period. Generic drugs are also widely used in supportive care during the chemotherapy treatment for oncology. According to the Indian Council for Medical Research (ICMR), in India, the number of Indians who have cancer is projected to increase from 26.7 billion in 2022. to 29.8 billion by 2025. As per the Pharma Intelligence Center, there are currently 1,351 generic drugs available in India for the treatment of various cancers as of February 26, 2021. Most drugs are for the treatment of hematological malignancies, such as blood cancer (606) and leukemia (428). As the cost of branded drugs is higher than generic drugs, maximum people cannot afford these branded drugs and consume generic drugs. Treatment of cancer is limited by the affordability of patients in many developing countries, including India. Therefore, generic drug manufacturers are manufacturing drugs available at affordable costs, often at less than 10% of the original brand cost. It is observed that there is a three-fold higher prescription of generic brands compared to innovators, accompanied by cost savings of up to 80% per prescription. However, the regulatory environment prevailing in India is favorable to ensure satisfactory generic products. These factors are responsible for the growth of this segment, which, eventually, is expected to aid the growth of branded generics market during the forecast period. The others segment is categorized into infectious diseases, musculoskeletal diseases, respiratory diseases, and oral health.
According to the Centers for Disease Control and Prevention, in 2018, ~100,000 people in the US suffered from various infectious diseases. Thus, the prevalence of infectious diseases and respiratory diseases, which are treated using generics, is mainly driving the others segment, contributing a considerable share in the branded generics market during the forecast period.
Market Opportunities of Global Branded Generics Market
The opportunity for global branded generics market is product differentiation. The pharmaceutical industry is one of the most intensively regulated sectors, and as a result of these challenges, returns on R&D investment in the pharmaceutical industry have decreased. One feasible alternative for addressing such challenges is adopting strategies such as product differentiation to reduce development costs and maximize profits. Product differentiation deals with developing innovative products based on an existing product by creating better features, performance, or efficacy. Product differentiation paves the way for strengthening product pipeline and lifecycle management. As generic drugs contain the same active pharmaceutical ingredients as the brand-name product, differentiation in the color, shape, taste, inactive ingredients, preservatives, and packaging result in high demand for branded generics globally. Therefore, differentiation in the final product is expected to offer lucrative growth opportunities for the competitive players in the branded generics market.
Additionally, prominent players in the market are focusing on offering low-cost branded generics to remain competitive in the market. This can be achieved by strategically sourcing raw materials from emerging economies and partnering with suppliers. The above factors support the overall branded generics market growth during the forecast period.
The Pan-Canadian Pharmaceutical Alliance, Canadian Generic Pharmaceutical Association, Centers for Disease Control and Prevention, US Food and Drug Administration, International Finance Corporation, and Indian Brand Equity Foundation are among the primary and secondary sources referred to while preparing the report on the global branded generics market.
Table of Contents
1. Introduction1.1 Study Scope
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Global Branded Generics Market - By Therapeutic Application
1.3.2 Global Branded Generics Market - By Distribution Channel
1.3.3 Global Branded Generics Market - By Drug Class
1.3.4 Global Branded Generics Market - By Formulation Type
1.3.5 Global Branded Generics Market - By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Branded Generics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East And Africa PEST Analysis
4.2.5 South And Central America PEST Analysis
4.3 Experts Opinion
5. Branded Generics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Penetration of Branded Generics
5.1.2 Increasing Government Initiatives for Promoting Branded Generics
5.2 Market Restraints
5.2.1 Switching Brands, Poorer Clinical Outcomes and Adverse Effects of Generic Medications
5.3 Market Opportunities
5.3.1 Product Differentiation
5.4 Future Trends
5.4.1 Encouraging Utility of Branded Generics by Healthcare Providers and Professionals
5.5 Impact Analysis
6. Branded Generics Market - Global Analysis
6.1 Global Branded Generics Market Revenue Forecast and Analysis
6.2 Global Branded Generics Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
6.4 Global Branded Generics Market - Market Potential Analysis, By Region
6.5 Comparative Company Analysis
6.6 Growth Strategy Analysis
6.7 Performance of Key Players
6.7.1.1 Teva Pharmaceuticals Industries Ltd.
6.7.1.2 Sandoz International GmbH
6.8 Market Share Analysis of Branded Generics Market
7. Global Branded Generics Market Revenue and Forecast To 2028 - by Therapeutic Application
7.1 Overview
7.2 By Therapeutic Application: Market Revenue and Forecast Analysis (US$ Billion)
7.3 Oncology
7.3.1 Overview
7.3.2 Oncology Market Revenue and Forecast to 2028 (US$ Billion)
7.4 Cardiovascular Diseases
7.4.1 Overview
7.4.2 Cardiovascular Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.5 Diabetes
7.5.1 Overview
7.5.2 Diabetes Market Revenue and Forecast to 2028 (US$ Billion)
7.6 Neurology
7.6.1 Overview
7.6.2 Neurology Market Revenue and Forecast to 2028 (US$ Billion)
7.7 Gastrointestinal Diseases
7.7.1 Overview
7.7.2 Gastrointestinal Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.8 Dermatology Diseases
7.8.1 Overview
7.8.2 Dermatology Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.9 Analgesics and Anti-Inflammatory
7.9.1 Overview
7.9.2 Analgesics and Anti-Inflammatory Market Revenue and Forecast to 2028 (US$ Billion)
7.10 Others
7.10.1 Overview
7.10.2 Others Market Revenue and Forecast to 2028 (US$ Billion)
8. Branded Generics Market Analysis and Forecast to 2028 by Distribution Channel
8.1 Branded Generics Market Revenue Share, by Distribution Channel (2022 and 2028)
8.2 Hospital Pharmacies
8.2.1 Overview
8.2.2 Hospital Pharmacies: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
8.3 Retail Pharmacies
8.3.1 Overview
8.3.2 Retail Pharmacies: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
8.4 Online Pharmacies
8.4.1 Overview
8.4.2 Online Pharmacies: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
8.5 Drug Stores
8.5.1 Overview
8.5.2 Drug Stores: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9. Branded Generics Market Analysis and Forecast to 2028 by Drug Class
9.1 Branded Generics Market Revenue Share, by Drug Class (2022 and 2028)
9.2 Alkylating Agents
9.2.1 Overview
9.2.2 Alkylating Agents: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.3 Antimetabolites
9.3.1 Overview
9.3.2 Antimetabolites: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.4 Hormones
9.4.1 Overview
9.4.2 Hormones: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.5 Anti-hypertensive
9.5.1 Overview
9.5.2 Anti-hypertensive: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.6 Lipid Lowering Drugs
9.6.1 Overview
9.6.2 Lipid Lowering Drugs: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.7 Anti-Depressants
9.7.1 Overview
9.7.2 Anti-Depressants: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.8 Anti-psychotics
9.8.1 Overview
9.8.2 Anti-psychotics: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.9 Anti-epileptic
9.9.1 Overview
9.9.2 Anti-epileptic: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.10 Others
9.10.1 Overview
9.10.2 Others: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
10. Global Branded Generics Market Analysis and Forecast to 2028 - by Formulation Type
10.1 Overview
10.2 Branded Generics Market Revenue Share, by Formulation Type (2022 and 2028)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Billion)
10.4 Parenteral
10.4.1 Overview
10.4.2 Parenteral Market Revenue and Forecast to 2028 (US$ Billion)
10.5 Topical
10.5.1 Overview
10.5.2 Topical Market Revenue and Forecast to 2028 (US$ Billion)
10.6 Others
10.6.1 Overview
10.6.2 Others Market Revenue and Forecast to 2028 (US$ Billion)
11. Branded Generics Market Revenue and Forecasts to 2028 Geographical Analysis
11.1 North America: Branded Generics Market
11.1.1 Overview
11.1.2 North America: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.1.3 North America: Branded Generics Market, by Therapeutic Application, 2019 - 2028 (US$ Billion)
11.1.4 North America: Branded Generics Market, by Distribution Channel, 2019 - 2028 (US$ Billion)
11.1.5 North America: Branded Generics Market, by Drug Class, 2019 - 2028 (US$ Billion)
11.1.6 North America: Branded Generics Market, by Formulation Type, 2019 - 2028 (US$ Billion)
11.1.7 North America: Branded Generics Market, by Country, 2022 & 2028 (%)
11.1.7.1 US: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.1.7.1.1 Overview
11.1.7.1.2 US: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.1.7.1.3 US: Branded Generics Market, by Therapeutic Application, 2019 - 2028 (US$ Billion)
11.1.7.1.4 US: Branded Generics Market, by Distribution Channel, 2019 - 2028 (US$ Billion)
11.1.7.1.5 US: Branded Generics Market, by Drug Class, 2019 - 2028 (US$ Billion)
11.1.7.1.6 US: Branded Generics Market, by Formulation Type, 2019 - 2028 (US$ Billion)
11.1.7.2 Canada: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.1.7.2.1 Overview
11.1.7.2.2 Canada: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.1.7.2.3 Canada: Branded Generics Market, by Therapeutic Application, 2019 - 2028 (US$ Billion)
11.1.7.2.4 Canada: Branded Generics Market, by Distribution Channel, 2019 - 2028 (US$ Billion)
11.1.7.2.5 Canada: Branded Generics Market, by Drug Class, 2019 - 2028 (US$ Billion)
11.1.7.2.6 Canada: Branded Generics Market, by Formulation Type, 2019 - 2028 (US$ Billion)
11.1.7.3 Mexico: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.1.7.3.1 Overview
11.1.7.3.2 Mexico: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.1.7.3.3 Mexico: Branded Generics Market, by Therapeutic Application, 2019 - 2028 (US$ Billion)
11.1.7.3.4 Mexico: Branded Generics Market, by Distribution Channel, 2019 - 2028 (US$ Billion)
11.1.7.3.5 Mexico: Branded Generics Market, by Drug Class, 2019 - 2028 (US$ Billion)
11.1.7.3.6 Mexico: Branded Generics Market, by Formulation Type, 2019 - 2028 (US$ Billion)
11.2 Europe: Branded Generics Market
11.2.1 Overview
11.2.2 Europe: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.2.3 Europe: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
11.2.4 Europe: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
11.2.5 Europe: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.2.6 Europe: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.2.7 Europe: Branded Generics Market, by Country, 2022 & 2028 (%)
11.2.7.1 Germany: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.1.1 Germany: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.1.2 Germany: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.1.3 Germany: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.1.4 Germany: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.1.5 Germany: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.2 France: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.2.1 France: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.2.2 France: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.2.3 France: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.2.4 France: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.2.5 France: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.3 UK: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.3.1 UK: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.3.2 UK: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.3.3 UK: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.3.4 UK: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.3.5 UK: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.4 Italy: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.4.1 Italy: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.4.2 Italy: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.4.3 Italy: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.4.4 Italy: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.4.5 Italy: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.5 Spain: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.5.1 Spain: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.5.2 Spain: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.5.3 Spain: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.5.4 Spain: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.5.5 Spain: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.6 Rest of Europe: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.6.1 Rest of Europe: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.6.2 Rest of Europe: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.6.3 Rest of Europe: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.6.4 Rest of Europe: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.2.7.6.5 Rest of Europe: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.3 Asia Pacific Branded Generics Market Revenue and Forecasts To 2028
11.3.1 Overview
11.3.2 Asia Pacific Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.3.3 Asia Pacific: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.3.4 Asia Pacific: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.3.5 Asia Pacific: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.3.6 Asia Pacific: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.3.7 Asia Pacific: Branded Generics Market Revenue and Forecasts to 2028, By Country (%)
11.3.7.1 Japan: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.3.7.1.1 Overview
11.3.7.1.2 Japan: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.3.7.1.3 Japan: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.3.7.1.4 Japan: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.3.7.1.5 Japan: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.3.7.1.6 Japan: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.3.7.2 China: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.3.7.2.1 Overview
11.3.7.2.2 China: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.3.7.2.3 China: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.3.7.2.4 China: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.3.7.2.5 China: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.3.7.2.6 China: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.3.7.3 India Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.3.7.3.1 Overview
11.3.7.3.2 India: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.3.7.3.3 India: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.3.7.3.4 India: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.3.7.3.5 India: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.3.7.3.6 India: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.3.7.4 South Korea: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.3.7.4.1 Overview
11.3.7.4.2 South Korea: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.3.7.4.3 South Korea: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.3.7.4.4 South Korea: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.3.7.4.5 South Korea: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.3.7.4.6 South Korea: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.3.7.5 Australia: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.3.7.5.1 Overview
11.3.7.5.2 Australia: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.3.7.5.3 Australia: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.3.7.5.4 Australia: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.3.7.5.5 Australia: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.3.7.5.6 Australia: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.3.7.6 Rest of Asia Pacific: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.3.7.6.1 Overview
11.3.7.6.2 Rest of Asia Pacific: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.3.7.6.3 Rest of Asia Pacific: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.3.7.6.4 Rest of Asia Pacific: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.3.7.6.5 Rest of Asia Pacific: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.3.7.6.6 Rest of Asia Pacific: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.4 Middle East & Africa: Branded Generics Market Revenue and Forecast To 2028
11.4.1 Overview
11.4.2 Middle East & Africa: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.4.3 Middle East & Africa: Branded Generics Market, by Therapeutic Application, 2019 - 2028 (US$ Billion)
11.4.4 Middle East & Africa: Branded Generics Market, by Distribution Channel, 2019 - 2028 (US$ Billion)
11.4.5 Middle East & Africa: Branded Generics Market, by Drug Class, 2019 - 2028 (US$ Billion)
11.4.6 Middle East & Africa: Branded Generics Market, by Formulation Type, 2019 - 2028 (US$ Billion)
11.4.7 Middle East & Africa: Branded Generics Market, by Country, 2022 & 2028 (%)
11.4.7.1 UAE: Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
11.4.7.1.1 Overview
11.4.7.1.2 UAE: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.4.7.1.3 UAE: Branded Generics Market, by Therapeutic Application, 2019 - 2028 (US$ Billion)
11.4.7.1.4 UAE: Branded Generics Market, by Distribution Channel, 2019 - 2028 (US$ Billion)
11.4.7.1.5 UAE: Branded Generics Market, by Drug Class, 2019 - 2028 (US$ Billion)
11.4.7.1.6 UAE: Branded Generics Market, by Formulation Type, 2019 - 2028 (US$ Billion)
11.4.7.2 Saudi Arabia: Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
11.4.7.2.1 Overview
11.4.7.2.2 Saudi Arabia: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.4.7.2.3 Saudi Arabia: Branded Generics Market, by Therapeutic Application, 2019 - 2028 (US$ Billion)
11.4.7.2.4 Saudi Arabia: Branded Generics Market, by Distribution Channel, 2019 - 2028 (US$ Billion)
11.4.7.2.5 Saudi Arabia: Branded Generics Market, by Drug Class, 2019 - 2028 (US$ Billion)
11.4.7.2.6 Saudi Arabia: Branded Generics Market, by Formulation Type, 2019 - 2028 (US$ Billion)
11.4.7.3 South Africa: Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
11.4.7.3.1 Overview
11.4.7.3.2 South Africa: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.4.7.3.3 South Africa: Branded Generics Market, by Therapeutic Application, 2019 - 2028 (US$ Billion)
11.4.7.3.4 South Africa: Branded Generics Market, by Distribution Channel, 2019 - 2028 (US$ Billion)
11.4.7.3.5 South Africa: Branded Generics Market, by Drug Class, 2019 - 2028 (US$ Billion)
11.4.7.3.6 South Africa: Branded Generics Market, by Formulation Type, 2019 - 2028 (US$ Billion)
11.4.7.4 Rest of Middle the East and Africa: Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
11.4.7.4.1 Overview
11.4.7.4.2 Rest of Middle East & Africa: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
11.4.7.4.3 Rest of Middle East & Africa: Branded Generics Market, by Therapeutic Application, 2019 - 2028 (US$ Billion)
11.4.7.4.4 Rest of Middle East & Africa: Branded Generics Market, by Distribution Channel, 2019 - 2028 (US$ Billion)
11.4.7.4.5 Rest of Middle East & Africa: Branded Generics Market, by Drug Class, 2019 - 2028 (US$ Billion)
11.4.7.4.6 Rest of Middle East & Africa: Branded Generics Market, by Formulation Type, 2019 - 2028 (US$ Billion)
11.5 South and Central America Branded Generics Market Revenue and Forecast to 2028
11.5.1 Overview
11.5.2 South & Central America Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.5.3 South & Central America: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.5.4 South & Central America: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.5.5 South & Central America: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.5.6 South & Central America: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.5.7 South & Central America: Branded Generics Market Revenue and Forecasts to 2028, By Country (%)
11.5.7.1 Argentina Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
11.5.7.1.1 Overview
11.5.7.1.2 Argentina: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.5.7.1.3 Argentina: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.5.7.1.4 Argentina: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.5.7.1.5 Argentina: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.5.7.1.6 Argentina: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.5.7.2 Brazil: Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
11.5.7.2.1 Overview
11.5.7.2.2 Brazil: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.5.7.2.3 Brazil: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.5.7.2.4 Brazil: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.5.7.2.5 Brazil: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.5.7.2.6 Brazil: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
11.5.7.3 Rest of South and Central America: Branded Generics Market - Revenue and Forecast to 2028 (USD Billion)
11.5.7.3.1 Overview
11.5.7.3.2 Rest of South & Central America: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)
11.5.7.3.3 Rest of South & Central America: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)
11.5.7.3.4 Rest of South & Central America: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)
11.5.7.3.5 Rest of South & Central America: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
11.5.7.3.6 Rest of South & Central America: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
12. Impact Of COVID-19 Pandemic on Branded Generics Market
12.1 North America: Impact Assessment of COVID-19 Pandemic
12.2 Europe: Impact Assessment of COVID-19 Pandemic
12.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
12.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
12.5 SAM: Impact Assessment of COVID-19 Pandemic
13. Branded Generics Market - Industry Landscape
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Company Profiles
14.1 MYLAN N.V.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 GlaxoSmithKline plc.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Bausch Health Companies Inc.
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Lupin
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Sanofi
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 ASTRAZENECA PLC.
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Dr. Reddy's Laboratories
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Par Pharmaceuticals, INC
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Sandoz International GMBH
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
14.11 Aspen Holdings
14.11.1 Key Facts
14.11.2 Business Description
14.11.3 Products and Services
14.11.4 Financial Overview
14.11.5 SWOT Analysis
14.11.6 Key Developments
14.12 Hetero
14.12.1 Key Facts
14.12.2 Business Description
14.12.3 Products and Services
14.12.4 Financial Overview
14.12.5 SWOT Analysis
14.12.6 Key Developments
15. Appendix
15.1 About the Publisher
15.2 Glossary of Terms
List of Tables
Table 1. North America Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
Table 2. North America Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Billion)
Table 3. North America Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
Table 4. North America Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
Table 5. US Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
Table 6. US Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
Table 7. US Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
Table 8. US Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
Table 9. Canada: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
Table 10. Canada Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
Table 11. Canada Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
Table 12. Canada Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
Table 13. Mexico: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
Table 14. Mexico Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
Table 15. Mexico Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
Table 16. Mexico Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
Table 17. Europe: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
Table 18. Europe: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
Table 19. Europe: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
Table 20. Europe: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
Table 21. Germany: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
Table 22. Germany: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
Table 23. Germany: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
Table 24. Germany: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
Table 25. France: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
Table 26. France: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
Table 27. France: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
Table 28. France: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
Table 29. UK: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
Table 30. UK: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
Table 31. UK: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
Table 32. UK: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
Table 33. Italy: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
Table 34. Italy: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
Table 35. Italy: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
Table 36. Italy: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
Table 37. Spain: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
Table 38. Spain: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
Table 39. Spain: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
Table 40. Spain: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
Table 41. Rest of Europe: Branded Generics Market, by Therapeutic Application - Revenue and Forecast to 2028 (US$ Billion)
Table 42. Rest of Europe: Branded Generics Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Billion)
Table 43. Rest of Europe: Branded Generics Market, by Drug Class - Revenue and Forecast to 2028 (US$ Billion)
Table 44. Rest of Europe: Branded Generics Market, by Formulation Type - Revenue and Forecast to 2028 (US$ Billion)
Table 45. Asia Pacific: Branded Generics Marke
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- MYLAN N.V.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- GlaxoSmithKline plc
- Bausch Health (Valeant Pharmaceuticals)
- Sandoz International Gmbh
- Aspen Holdings
- Par Pharmaceuticals
- Lupin
- Sanofi
- AstraZeneca
- Dr. Reddy's Laboratories Inc.
- Hetero
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 229 |
| Published | June 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 235.86 Million |
| Forecasted Market Value ( USD | $ 414.99 Million |
| Compound Annual Growth Rate | 9.9% |
| Regions Covered | Global |
